A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Trial Details

NCT ID
NCT06914037
Phase
PHASE1
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CHT101
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Willing and able to provide written informed consent.
  • Aged 18 to 70 years, male or female.
  • Confirmed CD70 positive in tumor tissue by immunohistochemistry (IHC).
  • Only the following subtypes of hematological malignancies with measurable disease will be enrolled:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →